Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
United States
/
Pharmaceuticals & Biotech
Create a narrative
Ocugen Community
NasdaqCM:OCGN Community
1
Narratives
written by author
0
Comments
on narratives written by author
52
Fair Values set
on narratives written by author
Community Investing Ideas
Ocugen
Popular
Undervalued
Overvalued
Ocugen
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
Gene Therapy Trials And Regulatory Approvals Will Open New Frontiers
Key Takeaways Progress in gene therapy development and regulatory engagement positions Ocugen for faster market entry, revenue growth, and strong long-term margins. In-house manufacturing and non-dilutive partnerships boost supply chain control and reduce reliance on shareholder dilution, supporting future earnings expansion.
View narrative
US$6.48
FV
84.4% undervalued
intrinsic discount
228.07%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
27
users have followed this narrative
3 months ago
author updated this narrative
Your Valuation for
OCGN
OCGN
Ocugen
Your Fair Value
US$
Current Price
US$1.01
11.0% overvalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
-110m
69m
2015
2018
2021
2024
2025
2027
2030
Revenue US$68.6m
Earnings US$14.4m
Advanced
Set Fair Value